Schrödinger stock skyrockets as Novartis invests billions in new partnership
In a landmark development, Schrödinger, Inc. has entered into a multi-target research collaboration and expanded software licensing agreement with Novartis AG, potentially valued at up ... Read More
Eli Lilly’s stock plummets over missed sales forecasts for Mounjaro, Zepbound – what’s next for the pharma giant?
Eli Lilly & Co. has faced a dramatic drop in its stock price, tumbling over 10% following a critical earnings report that highlighted missed revenue ... Read More
AbbVie makes bold move in Alzheimer’s market with $1.4bn Aliada buyout—Is it a gamble?
AbbVie, the renowned American biopharmaceutical giant, is set to acquire Aliada Therapeutics for a staggering $1.4 billion. The acquisition grants AbbVie control over Aliada’s promising ... Read More
UK approves Lilly’s Alzheimer’s drug but labels it ‘too expensive’ for NHS use
The UK has approved Eli Lilly's new Alzheimer’s treatment, donanemab, which has shown promise in slowing cognitive decline. However, the National Institute for Health and ... Read More
New hope for eczema sufferers as FDA approves Eli Lilly’s EBGLYSS
Eli Lilly and Company (Lilly) has secured approval from the U.S. Food and Drug Administration (FDA) for its new biologic treatment, EBGLYSS (lebrikizumab-lbkz), for moderate-to-severe ... Read More
Eli Lilly to expand manufacturing with $1bn investment in Ireland to boost Alzheimer’s drug production
Eli Lilly and Company (NYSE: LLY) has announced a substantial $1 billion investment to expand its Limerick, Ireland, manufacturing site, which will increase the production ... Read More
Eli Lilly completes $3.2 billion acquisition of Morphic to enhance IBD treatments
Eli Lilly and Company has finalised its acquisition of Morphic Holding, Inc. in a landmark $3.2 billion deal, aimed at enhancing treatment options for inflammatory ... Read More
Eli Lilly to acquire Morphic in $3.2bn deal to expand integrin therapy development
In a major strategic move, Eli Lilly and Company (NYSE: LLY) has announced a definitive agreement to acquire Morphic Holding, Inc. (NASDAQ: MORF), a biopharmaceutical ... Read More
FDA approves Eli Lilly’s Kisunla for Alzheimer’s treatment
The U.S. Food and Drug Administration (FDA) has approved Kisunla (donanemab-azbt), an Alzheimer's treatment developed by Eli Lilly and Company (NYSE: LLY). This treatment, specifically ... Read More
Eli Lilly’s tirzepatide shows promising results for obstructive sleep apnea in latest clinical trials
Eli Lilly and Company (NYSE: LLY) has announced promising results from the SURMOUNT-OSA phase 3 clinical trials of tirzepatide, a novel treatment aimed at moderate-to-severe ... Read More